Mahar P S.
Role of Mitomycin-C in Reducing the Recurrence of Pterygium after Surgery.
Pak J Ophthalmol Jan ;12(3):91-4.

A prospective study was carried out on 64 eyes of 47 patients undergoing pterygium excision. Postoperatively, these eyes were randomized into two groups to receive two different strengths of topical Mitomycin-C (MMC) a non cell cycle-specific alkylating agent with an antiproliferative effect on cells showing increased rate of mitosis. in group 1, 36 eyes comprising 33 primary and 3 recurrent pterygia received MMC 0.04% one drop 4 times a day for 5 days and showed no recurrence of pterygium at mean follow-up of 18 months. Two patients had serious complications because of misuse of MMC. in group 2, 28 eyes with 23 pterygia of primary nature and 5 with recurrent pathology were treated with MMC 0.02%, one drop twice a day for 5 days. At mean follow-up of 11 months no recurrence was seen in patients with primary pterygia. However, all 5 Patients (18%) with recurrent pterygia showed further recurrence within the first six months of surgery. No untoward changes were witnessed in this group. Use of MMC does offer a simple and effective way of adjunctive therapy when compared to other means. Concentration of MMC 0.02% appears to be adequate in reducing the recurrence of pterygia of primary nature. However, when treating a recurrent pathology one might consider using MMC in higher concentration of 0.04%.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com